Table 2.
Analysis of published evidence on MFM’s measurement properties depending on the diagnosis
| All NMD | DMD | DM1 | SMA | FSHD | CMT | CMD, CM | |
|---|---|---|---|---|---|---|---|
| Structural validity | + Moderate | ? Moderate | + High | ? No evidence | + High Ceiling effect especially for D2 and D3 | + High | + Moderate |
| Internal consistency | + High | ? Moderate | ? No evidence | + High | ? No evidence | ? No evidence | + High |
| Reliability | + High | ? Low | ? No evidence | + High | ? No evidence | ? No evidence | Inter-rater: + Intra-rater: ? Moderate |
| Cross-cultural validity | Low | ? No evidence | ? No evidence | ? No evidence | ? No evidence | ? No evidence | ? No evidence |
| Criterion validity | ? No evidence | ? No evidence | ? No evidence | ? No evidence | ? No evidence | ? No evidence | ? No evidence |
| Convergent validity | + High | ? No evidence | ? No evidence | + High | + Moderate | ? No evidence | + High |
| Discriminant validity | + High | ? No evidence | ? No evidence | + High | ? No evidence | ? No evidence | + High Floor and ceiling effect |
| Responsiveness | + High | + High | ? No evidence | + High | Low | CMT1: − CMT2:+ High |
+ Moderate |
| Measurement error | ? No evidence | ? No evidence | ? No evidence | ? No evidence | ? No evidence | ? No evidence | ? No evidence |
GRADE level of evidence: green: high, orange: moderate, red: low, grey: no evidence. Rating of measurement properties: +: sufficient, ?: indeterminate, –: low. NMD: neuromuscular disease, CMD: congenital muscular dystrophy, CM: congenital myopathy, DM1: myotonic dystrophy type 1, SMA: spinal muscular atrophy, FSHD: facio-scapulo-humeral dystrophy, CMT: Charcot-Marie-Tooth disease, DMD: Duchenne muscular dystrophy.